[{"orgOrder":0,"company":"DiscGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Discogenic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiscGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Undisclosed"},{"orgOrder":0,"company":"DiscGenics","sponsor":"CTI Clinical Trial and Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Discogenic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiscGenics \/ CTI Clinical Trial and Consulting","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ CTI Clinical Trial and Consulting"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Rebonuputemcel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"DiscGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Undisclosed"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rebonuputemcel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"DiscGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Undisclosed"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Rebonuputemcel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"DiscGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by DiscGenics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IPEX Indonesia
                          Not Confirmed
                          IPEX Indonesia
                          Not Confirmed

                          Details : Rebonuputemcel is an allogeneic, injectable disc progenitor cell therapy, is under investgaten for painful lumbar degenerative disc disease.

                          Product Name : IDCT

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          July 16, 2024

                          Lead Product(s) : Rebonuputemcel

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IPEX Indonesia
                          Not Confirmed
                          IPEX Indonesia
                          Not Confirmed

                          Details : High dose IDCT (Allogeneic Discogenic Progenitor Cell Therapy) also produced clinically meaningful, statistically significant improvements in function and quality of life by 12 weeks following intradiscal injection with durability sustained at the one-ye...

                          Product Name : IDCT

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          October 11, 2022

                          Lead Product(s) : Rebonuputemcel

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IPEX Indonesia
                          Not Confirmed
                          IPEX Indonesia
                          Not Confirmed

                          Details : This prospective, randomized, double-blinded, sham-controlled, multicenter clinical study is designed to evaluate the safety and preliminary efficacy of IDCT in patients with symptomatic, single-level, mild to moderate lumbar disc degeneration.

                          Product Name : IDCT

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          April 27, 2021

                          Lead Product(s) : Rebonuputemcel

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Discogenic Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Intervertebral Disc Degeneration.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          May 20, 2019

                          Lead Product(s) : Discogenic Cell

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IPEX Indonesia
                          Not Confirmed
                          IPEX Indonesia
                          Not Confirmed

                          Details : Discogenic Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Intervertebral Disc Degeneration.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          November 20, 2017

                          Lead Product(s) : Discogenic Cell

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I

                          Sponsor : CTI Clinical Trial and Consulting

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank